NICE has said it expects to evaluate dozens of potential treatments for Alzheimer’s disease over the next few years. Elisabeth Mahase examines what we know about these drugs This year the National ...
10don MSN
The UK’s drugs regulator – the MHRA – has approved the Alzheimer’s drug donanemab, but it won’t be available on the NHS.
Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...
Metabolic and vascular disorders are risk factors for AD, and it has been suggested that medications ... combination therapy ...
An Alzheimer’s drug from Roche cleared a protein that’s a hallmark of the disease from patients’ brains, suggesting the drug ...
U.S. drugmaker AbbVie said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental ...
The purchase is the latest in a slew of efforts to invest in its neuroscience portfolio as Humira faces generic competition.
A small tweak in the dosing regimen of Eli Lilly’s Alzheimer’s disease drug Kisunla has reduced brain swelling of patients in ...
After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.
AbbVie (ABBV) announced Monday that it is buying Aliada Therapeutics for $1.4 billion. The deal includes Aliada’s lead drug ...
The results were pretty astounding: Patients who used Ozempic had a whopping 70% lower risk of Alzheimer's than patients who ...
With a new way to break the blood-brain barrier, an Aliada Therapeutics deal could give the North Chicago drugmaker's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback